Leo Pranitis, Prisyna’s GM interviewed by Dr. Howard Farran of DentalTown

CLAREMONT, Calif. – November 6, 2019 – Recently, Prisyna’s General Manager Leo Pranitis was interviewed by Dr. Howard Farran of DentalTown. Leo discusses how he is leveraging his 25-year career in the oral healthcare arena to now successfully commercialize Moisyn, Synedent, and Synedent FLX.

About Prisyna 

Prisyna, the oral healthcare division of Synedgen, is developing and commercializing a new class of oral health care products based on glycomics, a revolutionary approach using natural glycopolymers to target the mucosal interface. Prisyna uses this unique technology to develop oral health care products that clean the mouth, reduce pain and irritation on sensitive mucosal surfaces and improve overall oral health. Prisyna is building a family of environmentally safe products using cutting edge science to promote healthy teeth, gums and oral surfaces. http://www.prisyna.com/

Media Contact: 

Leo Pranitis General Manager, Prisyna 909.477.6858 leo.pranitis@prisyna.com

Prisyna’s GM, Leo Pranitis talks about ChitoTek

CLAREMONT, Calif. – October 17, 2019 – Prisyna’s General Manager, Leo Pranitis, talks about why the innovative ChitoTek™ molecule that is found in Moisyn® Dry Mouth and Synedent® Mouthwash is so effective. Prisyna is leveraging the science that continues to be proven out in the medical arena through its parent company, Synedgen.

 

About Prisyna 

Prisyna, the oral healthcare division of Synedgen, is developing and commercializing a new class of oral health care products based on glycomics, a revolutionary approach using natural glycopolymers to target the mucosal interface. Prisyna uses this unique technology to develop oral health care products that clean the mouth, reduce pain and irritation on sensitive mucosal surfaces and improve overall oral health. Prisyna is building a family of environmentally safe products using cutting edge science to promote healthy teeth, gums and oral surfaces. http://www.prisyna.com/

Media Contact: 

Leo Pranitis General Manager, Prisyna 909.477.6858 leo.pranitis@prisyna.com

Leo Pranitis, GM of Prisyna discusses Moisyn for dry mouth relief with Amber Auger, MPH, RDH

CLAREMONT, Calif. – September 13, 2019 – Leo Pranitis, General Manager of Prisyna Oral Healthcare, spoke with Amber Auger, MPH, RDH, during the RDH Under One Roof Annual Meeting on August 2, 2019 in Dallas, Tx. They discussed Prisyna’s unique and patented molecule, ChitoTek, and how that innovation is providing greater options for patients and practitioners alike. 

About Prisyna 

Prisyna, the oral healthcare division of Synedgen, is developing and commercializing a new class of oral health care products based on glycomics, a revolutionary approach using natural glycopolymers to target the mucosal interface. Prisyna uses this unique technology to develop oral health care products that clean the mouth, reduce pain and irritation on sensitive mucosal surfaces and improve overall oral health. Prisyna is building a family of environmentally safe products using cutting edge science to promote healthy teeth, gums and oral surfaces. http://www.prisyna.com/

Media Contact: 

Leo Pranitis General Manager, Prisyna 909.477.6858 leo.pranitis@prisyna.com

Synedgen’s Glycopolymer Technology Licensed to Synspira Therapeutics Demonstrates Improvement in Abnormal Cystic Fibrosis Mucus and Pulmonary Disease

Synspira Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis and other rare diseases, today announced the results of a publication exploring the efficacy of SNSP113 as a potential treatment for improving lung function in people with cystic fibrosis. The publication, “A glycopolymer improves viscoelasticity and mucociliary transport of abnormal cystic fibrosis mucus” was published in the April issue of The Journal of Clinical Investigation and evaluated a number of mechanisms where SNSP113 could impact abnormal mucus structure and improve mucus clearance.

Prisyna Announces Publication of Research Demonstrating Synvaza’s Effect on Oral Lesion Relief

— Synvaza reduces pain associated with erosive or ulcerative oral lesions —

CLAREMONT, Calif. – July 11, 2018 – Prisyna, the oral care division of Synedgen, founded to optimize oral health using advanced, proprietary glycomics technology, today announced new research showing that Synvaza®, an oral rinse product, reduced mucosal pain without anesthetic effect and improved oral function in patients with ulcerative oral mucosal lesions. The study, “Efficacy of a glycopolymer-based oral rinse upon pain associated with ulcerative and erosive lesions of the oral mucosa: A within-subject pilot study,” was published in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.

The pilot study was powered to evaluate the efficacy of Synvaza in reducing pain associated with existing erosive or ulcerative lesions of the oral mucosa and to understand the magnitude of the effect on pain reduction in order to power future studies. Results showed that Synvaza significantly reduced severity in all measures of oral soreness from baseline to 72 hours.

Twenty-five subjects with ulcerative/erosion lesions and moderate pain were enrolled in this open label study. They were provided with a 72-hour supply of Synvaza and instructed to use as needed for 72 hours with a minimum frequency of two times per day, swished for one minute at each use, with the first dose used upon awakening and the last dose just before bedtime. At the start of the study, and 24, 48 and 72 hours after first product use, subjects completed surveys in which they documented pain scores and oral symptoms, including mouth and throat soreness, domain-specific problems with eating, drinking, swallowing, talking, sleeping, and general symptoms of dry mouth and mouth and throat lining sensitivity and pain. Ratings ranged from zero, representing an absence of symptoms, to ten, representing the most severe degree of symptoms.

The overall soreness score showed a continuous decline across the four-time points and all of the oral soreness scores had a statistically significant decrease from baseline to 72 hours. The largest domain-specific decrease from baseline to 72 hours was for oral soreness associated with talking (67%), followed by drinking (62%), swallowing (56%), sleeping (51%), and eating (50%). Overall soreness from baseline to 72 hours decreased by 28%.

“The study showed reductions in mouth or throat pain, changes in dry mouth and sensitivity of the lining of the mouth and throat to spicy, hot or acidic foods, which may represent a meaningful improvement in quality of life for patients,” said lead author Joel B. Epstein, DMD, MSD. “Additionally, early pain reduction was commonly reported, with a cumulative effect that appeared to increase with successive rinse applications for the duration of the study, implying a potentially broad range of effect upon painful oral mucosal conditions.”

“Synvaza addresses the needs of patients who suffer from the pain of oral lesions, which can have a substantial negative effect on their daily routine and in more acute circumstances can be quite debilitating,” stated Leo Pranitis, Prisyna General Manager. “We look forward to the continued study and development of Synvaza to potentially provide relief for patients suffering from ulcerative oral mucosal lesions as part of our commitment to addressing a broad range of patient oral care needs using our innovative glycomics technology.”

Disclosure: Synedgen Inc. provided funding for this research and contributed to the protocol design, development and manuscript. Data were analyzed and interpreted independently. The National Institutes of Health / National Institute of Dental & Craniofacial Research supported oral mucositis research under Grant Number:2R44DE019740-02.

Prisyna Receives FDA 510(k) Clearance for Moisyn Product Line to Treat Dry Mouth

— Company’s innovative glycomics technology now addresses large population suffering from xerostomia —

CLAREMONT, Calif. – May 9, 2018– Prisyna, the oral care division of Synedgen, founded to optimize oral health using advanced, proprietary glycomics technology, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its family of Moisyn™ products designed to treat xerostomia.

Xerostomia (also known as dry mouth, or dry mouth syndrome) is an unpleasant and challenging oral health condition that occurs when there is a decrease in the presence of saliva. Dry mouth affects a large percentage of the adult population, and as much as half of the elderly population in the United States. The symptoms of dry mouth significantly impact patient quality of life and often cause difficulty in chewing, swallowing and speaking, and can result in dry, thick oral mucus, painful oral tissues, bad breath, and sleep disturbance.

“With the FDA clearance for Moisyn products, patients will have access to a new treatment that can alleviate the symptoms of dry mouth and improve their oral health,” said Leo Pranitis, General Manager of Prisyna. “We are now able to offer patients an innovative new option for treating xerostomia using the first glycomics targeted therapy that has been shown in a clinical study to reduce pain and increase comfort. Data from this clinical study further validates our vision to bring better outcomes to the oral healthcare community through our glycomics technology.”

In a clinical study where patients used Moisyn up to four times daily, statistically significant reductions occurred in symptoms associated with dryness, ability to eat and swallow, mouth sensation and taste. Key symptoms treated by Moisyn included reduced mouth pain, improved ability to sleep, and improved sense of taste. As a result of treatment with Moisyn, patients in the study reported a reduction in food becoming lodged in the throat due to dryness and a change in the saliva thickness, positively affecting food choices as well as the quality of sleep.[i]

“Xerostomia, or dry mouth, is a challenging and frustrating oral health care issue that affects up to 20 percent of the adult population and nearly 50 percent of the elderly population in the U.S.,” said Joel Epstein, DMD, MSD, and principal investigator of a Moisyn clinical study. “Many of these patients have medical conditions such as autoimmune diseases or diabetes that can cause dry mouth, and dry mouth may be seen in people being treated for diseases such as cancer or as a side effect of certain medications. For patients living with xerostomia Moisyn can relieve the symptoms of dry mouth and could be an important contribution to overall oral health.”

About Xerostomia (Dry Mouth)

Xerostomia, or dry mouth, causes dryness in the oral cavity, most commonly the tongue and roof of the mouth. Typically, it is identified by a reduction or absence of oral saliva and can be brought on by a variety of conditions, including aging. Over 1000 prescription and non-prescription medications, including drugs for treating anxiety, depression, high blood pressure, allergies, and cancer are known to alter the production of saliva and cause dry mouth as a side effect.

Common problems stemming from dry mouth include tooth decay, disturbed sleep, dry throat, burning sensation in the throat, gum disease, oral infections, taste change, and difficulty speaking and swallowing.

[i] Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Jan;123(1):76-83. doi: 10.1016/j.oooo.2016.09.008. Epub 2016 Sep 28.

Prisyna Appoints Leo Pranitis as General Manager

— Experienced healthcare executive to build oral health franchise and expand Prisyna brand —

CLAREMONT, Calif. – April 17, 2018 – Prisyna, the oral care division of Synedgen, founded to optimize oral health using advanced, proprietary glycomics technology, today announced the appointment of Leo Pranitis as General Manager. He will lead the commercialization and expansion of Prisyna’s product portfolio, including the Synedent™ family of products made of naturally-derived, environmentally compatible ingredients that disrupt oral contaminants, remove harmful debris, and promote healthy teeth and gums.

“As our oral care portfolio expands, we are very pleased to bring Leo Pranitis on board to grow the Prisyna brand and build consumer adoption of its products,” said Shenda Baker, Ph.D., Synedgen President and Chief Operating Officer. “Leo is a highly experienced oral care marketing professional with a proven track record of creating and executing intelligent commercialization campaigns that reach patients who can benefit from improved oral care products.”

Mr. Pranitis commented, “Synedgen’s innovative and ground-breaking glycomics platform is dedicated to delivering outstanding benefits to both patient and health care providers. As General Manager of Prisyna, I am thrilled to have the opportunity to bring this exciting science to meet the oral care needs of patients and I look forward to introducing new oral care products as we continue to build on the science of glycomics.”

Mr. Pranitis has over 30 years of professional experience in various commercial roles, primarily within the dental industry. He has built and led sales, marketing and R&D teams that have produced award-winning, market-leading products, several of which continue to hold premier market share positions within the global dental market. Previous roles include Vice President of Sales & Marketing, North America, for Southern Dental Industries, Vice President, Sales & Marketing for Sonendo, and Vice President, Global Marketing and Innovation at Kavo Kerr (previously, Kerr Dental), a Danaher company. Mr. Pranitis holds a B.A. from Northern Illinois University, and is the co-inventor of the world’s first single dose dental adhesive system.

Prisyna announces new Synedent FLX Mouthwash With Fluoride

New Product, New Look, New Larger Bottles

October 31, 2017 Claremont CA—Prisyna today announces the upcoming launch of its latest product, Synedent FLX®. Synedent FLX was developed in response to customers’ requests for fluoride and in order to bring another layer of protection to the oral care line. Synedent FLX provides all the benefits of original Synedent, now with fluoride to help prevent cavities.

Continue reading “Prisyna announces new Synedent FLX Mouthwash With Fluoride”

Synedgen to Present New Treatment Options for Gastrointestinal Radiation Injury

Innovative Treatment to Reduce Cancer Therapy Complications

Radiotherapy is a well-established treatment for cancer, however pelvic radiotherapy can result in radiation proctitis, or inflammation and damage to the lower parts of the colon, for as many as 75% of radiation treated patients. In severe cases, this complication can result in the need to reduce the intensity of radiotherapy, ultimately jeopardizing a successful cancer prognosis.

Synedgen researchers are developing targeted therapies to reduce the incidence and severity of radiation proctitis by enhancing repair of gastrointestinal damage and modulating inflammation to allow for complete treatment or more aggressive treatment of pelvic cancers currently limited by radiation proctitis.

A poster presentation detailing this research has been accepted for display at Digestive Disease Week (DDW) 2016 at the San Diego Convention Center. The poster, entitled “Novel Therapeutic for the Repair of Gastrointestinal Radiation Injury”, will be exhibited on May 22, 2016 from 9:30 AM to 4:00 PM; lead author VP of Research Stacy Townsend PhD will be on hand to discuss the results from noon-2:00 PM.

The presentation highlights the efficacy of a specific molecule in Synedgen’s new class of targeted GI drugs, PAAG, on animal models of radiation proctitis. PAAG administered either orally or via enema significantly reduced local and systemic inflammation, and endoscopic examination confirmed improvement in the severity of proctitis compared to the control. A comparison between oral and enema administration showed that while both forms of treatment were highly effective, the oral delivery appears to be the optimal administration method.

“PAAG is a promising new drug candidate for reducing the inflammation and gastrointestinal damage associated with radiation therapy affecting the lower bowel,” stated Townsend. “We will continue to investigate its mechanisms of action in reducing radiation proctitis to enhance the development of this critically needed therapy.”

About Synedgen

Synedgen Inc. is an innovative biopharmaceutical company focused on targeting the mucosal interface to treat genetic and acquired disorders in the lungs and digestive tract. Synedgen’s Glycomics Technology Platform produces targeted drugs to meet unmet needs in treating inflammation, infection and mucosal damage. Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at www.synedgen.com.

About Digestive Disease Week

DDW is the world’s largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Approximately 15,000 GI professionals attended DDW 2015, plus an additional 2,000 to 3,000 exhibitors.